Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial: O189


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles